Home › Funds › Parkman Healthcare Partners LLC › URGN

Parkman Healthcare Partners LLC position in URGN

UROGEN PHARMA LTD · Health Care

Parkman Healthcare Partners LLC reported holding 750,202 shares of URGN (UROGEN PHARMA LTD) in its Q3 2026 13F filing — a position valued at US$30.5M, representing 2.75% of its reported portfolio and ranking #8 among its reported holdings. Parkman Healthcare Partners LLC has disclosed URGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)750.20K sh
Reported value held$30.48M
Portfolio Weight2.75%
First reportedQ3 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Parkman Healthcare Partners LLC's URGN position evolved

Parkman Healthcare Partners LLC first disclosed a stake in URGN in Q3 2023 at 145,311 shares (US$2.0M). The position peaked in Q3 2026 at 750,202 shares, worth US$30.5M. Across 13 filings, Parkman Healthcare Partners LLC increased the stake 9 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 750,202 shares valued at US$30.5M — an increase of 576,138 shares quarter over quarter.. Notable position changes include a 128% increase in Q3 2025 (shares rose 17% over the following quarter), a 63% increase in Q1 2026 (shares rose 105% over the following quarter), a 331% increase in Q3 2026 (shares fell 36% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 145.31K $2.04M New
Q4 2023 175.50K $2.63M Add
Q1 2024 184.18K $2.76M Add
Q2 2024 274.46K $4.61M Add
Q3 2024 347.54K $4.41M Add
Q4 2024 369.86K $3.94M Add
Q1 2025 393.15K $4.35M Add
Q2 2025 176.70K $2.42M Reduce
Q3 2025 402.60K $8.03M Add
Q4 2025 168.77K $3.95M Reduce
Q1 2026 275.00K $4.94M Add
Q2 2026 174.06K $6.41M Reduce
Q3 2026 750.20K $30.48M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About URGN and 13F data

URGN (UROGEN PHARMA LTD) is a Health Care company. 46 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$184.6M), Kynam Capital Management, LP (US$98.9M), Jefferies Financial Group Inc. (US$89.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding URGN

All URGN fund holders →

FAQ

How long has Parkman Healthcare Partners LLC held URGN?

Parkman Healthcare Partners LLC has disclosed URGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Parkman Healthcare Partners LLC's current position in URGN?

As of Q3 2026, Parkman Healthcare Partners LLC holds 750.20K shares of URGN (UROGEN PHARMA LTD), valued at $30.48M, representing 2.75% of its reported portfolio and ranking #8.

Has Parkman Healthcare Partners LLC been buying or selling URGN?

In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC increased its position in URGN. The position peaked in Q3 2026 at 750.20K shares.

Which other funds hold URGN?

Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.